Materials Science and Engineering B xxx (2008) xxx-xxx

Contents lists available at ScienceDirect



Materials Science and Engineering B

journal homepage: www.elsevier.com/locate/mseb



Aryl-derivatized, water-soluble functionalized carbon nanotubes for biomedical applications

N. Karousis^a, H. Ali-Boucetta^b, K. Kostarelos^{b,*}, N. Tagmatarchis^{a,*}

^a Theoretical and Physical Chemistry Institute, National Hellenic Research Foundation, 48 Vass. Constantinou Avenue, 11635 Athens, Hellas
^b Nanomedicine Laboratory, Centre for Drug Delivery Research, The School of Pharmacy, University of London, London WC1N 1AX, United Kingdom

ARTICLE INFO

Keywords: Nanotubes Functionalization Aryl diazonium salts Water soluble Biomedical applications

ABSTRACT

The functionalization of very-thin multi-walled carbon nanotubes (VT-MWNTs) with an aniline derivative, via the protocol of *in situ* generated aryl diazonium salts results, upon acidic deprotection of the terminal BOC group, on the formation of the water-soluble positively charged ammonium functionalized VT-MWNTs-NH₃⁺ material. The new materials have been structurally and morphologically characterized by infra-red (ATR-IR) spectroscopy and transmission electron microscopy (TEM). The quantitative calculation of the grafted aryl units onto the skeleton of VT-MWNTs has been estimated by thermogravimetric analysis (TGA), while the quantitative Kaiser test showed the amine group loaded onto VT-MWNTs-NH₃⁺ material. The aqueous solubility of this material has allowed the performance of some initial toxicological *in vitro* investigations.

© 2008 Elsevier B.V. All rights reserved.

1. Introduction

Since their discovery, carbon nanotubes (CNTs) have attracted considerable attention due to their unique chemical and physical properties as well as their promise in the area of materials chemistry [1,2]. Additionally, CNTs have been explored for possible applications in nanobiotechnology [3], as biosensors [4] and as drug and gene delivery systems [5–8]. However, CNTs must first be functionalized [9–11] and thus adequately dispersed in physiological media in order to be able to interact with cells and lead to cellular internalization in the absence of toxicity. In fact, it is known that CNTs accumulate in the cytoplasm and can even reach the nucleus, without being cytotoxic (in concentrations up to 10 mM) [12]. Thus, CNTs can potentially act as carriers that transport and deliver other bioactive components into cells [13].

An effective way of functionalization of CNTs introduced by Tour and coworkers [14–24] consists of the thermal reaction of *in situ* generated aryl diazonium compounds with CNTs, thus effecting the introduction of a plethora of aryl groups onto the sidewalls of the CNTs. The great advantages of this method are the high degree of functionalization, the solubilization enhancement and the variety of the substituted aryl compounds that can be used. Considering all the above, our aim is to functionalize very-thin multi-walled carbon nanotubes (abbreviated as VT-MWNTs) with the aniline derivative (**3**) according to Fig. 1. By this procedure, we can obtain hybrid material (**2**) en-route toward water-soluble functionalized VT-MWNTs to be biologically evaluated.

2. Experimental

2.1. General methods

All solvents and reagents were purchased from commercially available sources and used without further purification unless otherwise stated. Purified VT-MWNTs (diameter: 5–15 nm, purity >95%) were purchased by Nanocyl and used as received. Transmission electron microscopy images were collected with a Philips TEM 208 instrument at an accelerating voltage of 100 kV. Mid-infrared spectra in the region 550–4000 cm⁻¹ were obtained on a Fourier Transform infra-red (FT-IR) spectrometer (Equinox 55 from Bruker Optics) equipped with a single reflection diamond attenuated-total-reflectance (ATR) accessory (DuraSamp1IR II by SensIR Technologies). The thermogravimetric analysis was performed using a TGA Q500 V20.2 Build 27 instrument by TA in a nitrogen inert atmosphere.

2.2. Aryl functionalized VT-MWNTs-NHBOC (1)

In a typical experiment, 10 mg of VT-MWNTs suspended in 20 mL of 1,2-dichlorobenzene (ODCB) and sonicated for 20 min. Then, a solution of the aniline derivative (3) (0.5 mmol) in 10 mL of acetonitrile is added. After degassing the reaction mixture and

^{*} Corresponding authors. Tel.: +30 210 7273835; fax: +30 210 7273794. *E-mail address:* tagmatar@eie.gr (N. Tagmatarchis).

^{0921-5107/\$ –} see front matter $\ensuremath{\mathbb{C}}$ 2008 Elsevier B.V. All rights reserved. doi:10.1016/j.mseb.2008.06.002

N. Karousis et al. / Materials Science and Engineering B xxx (2008) xxx-xxx



Fig. 1. Functionalization scheme of VT-MWNTs with *in situ* generated aryl diazonium salts and formation of water-soluble cationic ammonium functionalized VT-MWNTs-NH₃⁺ (2).

bubbling with nitrogen, 0.8 mmol of isoamyl nitrite is quickly added and the suspension is stirred at 60 °C for 18 h. Then, after cooling to room temperature, the reaction mixture is diluted with 50 mL of dimethylformamide (DMF), filtered over a PTFE (0.2 μ m) membrane filter and washed extensively with DMF and CHCl₃ to remove any unbound organic material. Thus, the aryl functionalized VT-MWNTs-NHBOC (1) obtained as black solid on top of the filter.

2.3. Ammonium functionalized water-soluble VT-MWNTs- NH_3^+ (2)

The BOC protecting group of the functionalized VT-MWNTs-NHBOC (**1**) is cleaved by treatment with gaseous HCl of a CHCl₃ solution for 12 h. Evaporation of the highly acidic CHCl₃ solution, followed by addition of fresh dichloromethane with sonication, filtration through a 0.2 μ m PTFE membrane filter and eventually washing of the solid material collected on top of the filter with methanol, furnished the water-soluble positively charged ammonium functionalized VT-MWNTs-NH₃⁺ (**2**).

2.4. Human breast cancer cell cultures

The epithelial breast cancer derived MCF-7 cell lines were used for testing cell viability. Cells were cultured in MEM media supplemented with 2 mM glutamine, 5% foetal bovine serum (FBS) and $1 \times$ penicillin/streptomycin at 37 °C in 5% CO₂-humidified incubator.

2.5. Toxicology (MTT) assay

The MTT solution was prepared as 5 mg/mL in sterile PBS and subsequently sterilised via 0.2 µm filter and was stored in 2 mL aliquots at -20 °C. Dimethyl sulphoxide (DMSO) was used as the solubilization solution. MCF7 cells were seeded at a density of 40,000 cells/well in flat bottomed 96 well plates to a volume of 200 µL. Plates were left to allow cells to attach and grow by incubating them at 37 °C in 5% CO₂ for 24 h. Cells were treated with the VT-MWNTs solutions dispersed in 5% dextrose at a concentration range from 6.25 to $200 \,\mu g/mL$. Control wells were treated with complete media and the highest equivalent dextrose concentration. After 24 h, the medium was removed and replaced by 120 µL of MTT/media (20 µL MTT + 100 µL complete media) and incubated for 3:30 h to allow MTT reduction. A 100 µL of DMSO was then added to each well and left for 10 min at 37 °C to allow complete solubilization of the formazan product. The plate well was then measured for the optical densities at 570 nm using ELISA plate reader to determine the cell viability. This was represented as the percentage cell viability which is equal to (the optical density/mean control) \times 100.

3. Results and discussion

The aniline derivative (**3**), possessing the polar oligoethylene chain, was synthesized in two steps from 4-nitro benzoyl chloride and the mono-*tert*-butoxycarbonyl (BOC) protected ethylene glycol diamine [25]. The functionalized VT-MWNT material (**1**) is soluble in several solvents like chloroform, methanol and DMF, while the ink-colored water soluble functionalized VT-MWNT material (**2**) is stable for several weeks, that is without observing any significant precipitation.

The structure confirmation of the modified VT-MWNTs-NHBOC (**1**) is conducted by ATR-IR spectroscopy, where the presence of the added functional groups onto the skeleton of VT-MWNTs is verified. Thus, the characteristic C–H stretching and bending modes (2980–2920 cm⁻¹), as well as vibrations of the ethylene-glycol unit (1040–1530 cm⁻¹) along with the strong carbonyl vibration of the benzamide as well as the BOC protecting group (1649 and 1699 cm⁻¹, respectively), are observed. Importantly, in the ammonium functionalized VT-MWNTs (**2**), where the BOC protecting group is cleaved, the strong carbonyl vibration at 1699 cm⁻¹ is disappeared.

Transmission electron microscopy (TEM) is a meaningful means to probe the morphological characteristics of the functionalized VT-MWNTs. A representative TEM image of the soluble functionalized VT-MWNTs-NHBOC (1) is shown in Fig. 2. Evidently, VT-MWNTs of high purity with mean diameter of approximately 7 nm are identified, while the functionalized material does not suffer any degradation during the reaction conditions applied.

Thermogravimetric analysis (TGA) measurements of the ammonium functionalized material VT-MWNTs-NH₃⁺ (**2**) allowed the quantitative evaluation of the aryl moieties grafted onto the skeleton of VT-MWNTs (Fig. 3). In this frame, intact VT-MWNTs demonstrate excellent thermal stability up to 700 °C, while above that temperature start to slowly degrade. The VT-MWNTs-NH₃⁺ material (**2**) shows a two-step weight loss of approximately 67% to occur in the temperature range of 250–700 °C. The first thermal decomposition at the range 250–350 °C is attributed to the lost of aryl side chain, namely the ethylene glycol ammonium unit, while further thermal loss up to 700 °C is attributed to the decomposition of the benzamido-moiety coated the surface of VT-MWNTs. Thus, the percentage of the organic matter attached onto the skeleton of VT-MWNTs is calculated as 15 aryl units per every 100 carbon atoms of the VT-MWNTs.

The concentration of the terminal amino functions present on VT-MWNTs-NH₃⁺ material (**2**) is calculated with the aid of the quantitative Kaiser test. Thus, it is predicted the presence of 331 μ mol of free amino groups per gram of VT-MWNTs-NH₃⁺ (**2**).

2

N. Karousis et al. / Materials Science and Engineering B xxx (2008) xxx-xxx



Fig. 2. TEM image of soluble aryl functionalized VT-MWNTs-NHBOC (1).

Before any further biological investigation can take place, it is imperative to assess the limitations presented by the functionalized VT-MWNTs. The MTT assay is a well-established toxicological assay to assess cell viability based on the activity of mitochondrial enzymes [26–29]. Hence has been used by several groups to assess the toxicity of carbon nanotubes [30–33]. This assay is based on the conversion and cleavage of the tetrazolium salt MTT (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) into the purple formazan product by mitochondrial reductase of only living and metabolically active cells, observed as the purple color of the formazan that is measured at 570 nm. As can be seen from Fig. 4, the cell viability of MCF-7 is around 70–85% after 24 h treatment with the VT-MWNTs-NH₃⁺ (**2**) at all concentrations ranging from 6.25 to 200 µg/mL. Moreover, in control experiments, the high-



Fig. 3. Thermal gravimetric analysis of (a) pristine VT-MWNTs and (b) water-soluble cationic ammonium functionalized VT-MWNTs-NH₃⁺ (**2**).



Fig. 4. MCF-7 cell viability after 24 h treatment with aryl-functionalized VT-MWNTs-NH₃⁺ (2) at concentrations ranging from 6.25 to 200 μ g/mL per well.

est equivalent concentration of dextrose used without VT-MWNTs showed 100% MCF-7 cell viability over the 24-h period (data not shown). The high-cell viability expected with the improved solubility of VT-MWNTs-NH₃⁺ (**2**) indicates the suitability of using carbon nanotubes as components for biological experimentation, and agrees with previous observations that increasing the degree of functionalization of carbon nanotubes reduces their toxicity [31] and improves their biocompatibility [34]. These initial studies also indicate that the more aryl functionalities grafted on the surface of the nanotubes, the more improved the *in vitro* toxicity profile of carbon nanotubes and thereby their *in vivo* pharmacological profiles will be.

4. Conclusions

In summary, the functionalization of VT-MWNTs is achieved via *in situ* generated aryl diazonium salts of aniline derivative (**3**). The cleavage of the BOC protecting group liberates positively charged ammonium units at the side chain of the grafted aryl moieties onto the skeleton of the VT-MWNTs. The charged ammonium units as well as the hydrophilic nature of the ethylene glycol chain in (**2**) induce aqueous solubility. Spectroscopic characterization as well as thermal gravimetric analysis and electron microscopy measurements probed the structural and morphological characteristics of the new functionalized VT-MWNTs materials. Initial toxicological investigations indicated that further studies of such materials are warranted also confirming the general rule being formulated that functionalization of nanotubes improves dramatically the toxicity profile of this class of nanomaterials.

Acknowledgements

This work, conducted as part of the award ("Functionalization of Carbon Nanotubes Encapsulating Novel Carbon-based Nanostructured Materials") made under the European Heads of Research Councils and European Science Foundation EURYI (European Young Investigator) Awards scheme to NT, was supported by funds from the Participating Organizations of EURYI and the EC Sixth Framework Programme. HAB wishes to acknowledge the Ministére de l'Enseignement Supèrieur et de la Recherche Scientifique (Algeria) for a full PhD scholarship.

References

- M. Meyyappan, Carbon Nanotubes: Science and Applications, CRC Press, Boca Raton, FL, 2005.
- [2] E. Katz, I. Willner, Chem. Phys. Chem. 5 (2004) 1084.
- 3] G. Pagona, N. Tagmatarchis, Curr. Med. Chem. 13 (2006) 1789.
- [4] C.R. Martin, P. Kohli, Nat. Rev. Drug Discov. 2 (2003) 29.
 - 5] A. Bianco, K. Kostarelos, C.D. Partidos, M. Prato, Chem. Commun. (2005) 571.
 - [6] K. Kostarelos, L. Lacerda, C.D. Partidos, M. Prato, A. Bianco, J. Drug Deliv. Sci.
 - Technol. 15 (2005) 41.

4

N. Karousis et al. / Materials Science and Engineering B xxx (2008) xxx-xxx

- [8] A. Bianco, K. Kostarelos, M. Prato, Curr. Opin. Chem. Biol. 9 (2005) 674.
- [9] D. Tasis, N. Tagmatarchis, A. Bianco, M. Prato, Chem. Rev. 106 (2006) 1105.
- [10] D. Tasis, N. Tagmatarchis, V. Georgakilas, M. Prato, Chem. Eur. J. 9 (2003) 4000.
 [11] A. Hirsch, Angew. Chem. Int. 41 (2002) 1853.
- [12] K. Donaldson, R. Aitken, L. Tran, V. Stone, R. Duffin, G. Forrest, A. Alexander, Toxicol. Sci. 92 (1) (2006) 5.
- [13] N.W.S. Kam, H. Dai, J. Am. Chem. Soc. 127 (2005) 621.
- [14] J.L. Bahr, J. Yang, D.V. Kosynkin, M.J. Bronikowski, R.E. Smalley, J.M. Tour, J. Am. Chem. Soc. 123 (2001) 6536.
- [15] J.L. Bahr, J.M. Tour, Chem. Mater. 13 (2001) 3823.
- [16] J.L. Bahr, J.M. Tour, J. Mater. Chem. 12 (2002) 1952.
- [17] C.A. Dyke, J.M. Tour, J. Am. Chem. Soc. 125 (2003) 1156.
- [18] C.A. Dyke, J.M. Tour, Nano Lett. 3 (2003) 1215.
- [19] C.A. Dyke, J.M. Tour, Chem. Eur. J. 10 (2004) 812.
- [20] C.A. Dyke, M.P. Stewart, F. Maya, J.M. Tour, Synlett (2004) 155.
- [21] J.L. Hudson, M.J. Casavant, J.M. Tour, J. Am. Chem. Soc. 126 (2004) 11158.
- [22] C.A. Dyke, J.M. Tour, J. Phys. Chem. A 108 (2004) 11152.
- [23] B.K. Price, J.L. Hudson, J.M. Tour, J. Am. Chem. Soc. 127 (2005) 14867.

- [24] J.J. Stephenson, J.L. Hudson, S. Azad, J.M. Tour, Chem. Mater. 18 (2006) 374.
- [25] G. Pagona, N. Karousis, N. Tagmatarchis, Carbon 46 (2008) 604.
 [26] T. Mosmann, J. Immunol. Methods 65 (1983) 55.
- [27] F. Denizot, R. Lang, J. Immunol. Methods 89 (2007) 271.
- [28] D.T. Vistica, P. Skehan, D. Scudiero, A. Monks, A. Pittman, M.R. Boyd, Cancer Res. 51 (1991) 2515.
- [29] M.B. Hansen, S.E. Nielsen, K. Berg, J. Immunol. Methods 119 (1989) 203.
- [30] M. Davoren, E. Herzog, A. Casey, B. Cottineau, G. Chambers, H.J. Byrne, F.M. Lyng, Toxicol. In vitro 21 (2007) 438.
- [31] C.M. Sayes, F. Liang, J.L. Husdson, J. Mendez, W. Guo, J.M. Beach, V.C. Moore, C.D. Doyle, J.L. West, W.E. Billups, K.D. Ausman, V.L. Colvin, Toxicol. Lett. 161 (2006) 135.
- [32] D. Cui, F. Tian, C.O. Ozkan, M. Wang, H. Gao, Toxicol. Lett. 155 (2005) 73.
- [33] A. Magrez, S. Kasas, V. Salicio, N. Pasquier, J.W. Seo, M. Celio, S. Catsicas, B.
- Schwaller, L. Forro, Nano Lett. 6 (2006) 1121. [34] L. Lacerda, A. Bianco, M. Prato, K. Kostarelos, Adv. Drug Deliv. Rev. 58 (2006) 1460.